- Home
- CNNE vs ORKA Comparison
CNNE vs ORKA Comparison
Compare CNNE & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- ORKA
- Stock Information
- Founded
- CNNE 2014
- ORKA 2004
- Country
- CNNE United States
- ORKA United States
- Employees
- CNNE N/A
- ORKA N/A
- Industry
- CNNE Restaurants
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNNE Consumer Discretionary
- ORKA Health Care
- Exchange
- CNNE Nasdaq
- ORKA Nasdaq
- Market Cap
- CNNE 1.1B
- ORKA 1.2B
- IPO Year
- CNNE N/A
- ORKA N/A
- Fundamental
- Price
- CNNE $18.85
- ORKA $27.97
- Analyst Decision
- CNNE Buy
- ORKA Strong Buy
- Analyst Count
- CNNE 3
- ORKA 7
- Target Price
- CNNE $23.33
- ORKA $42.86
- AVG Volume (30 Days)
- CNNE 570.1K
- ORKA 517.8K
- Earning Date
- CNNE 11-11-2025
- ORKA 11-12-2025
- Dividend Yield
- CNNE 3.21%
- ORKA N/A
- EPS Growth
- CNNE N/A
- ORKA N/A
- EPS
- CNNE N/A
- ORKA N/A
- Revenue
- CNNE $437,200,000.00
- ORKA N/A
- Revenue This Year
- CNNE N/A
- ORKA N/A
- Revenue Next Year
- CNNE N/A
- ORKA N/A
- P/E Ratio
- CNNE N/A
- ORKA N/A
- Revenue Growth
- CNNE N/A
- ORKA N/A
- 52 Week Low
- CNNE $15.92
- ORKA $5.49
- 52 Week High
- CNNE $22.36
- ORKA $30.51
- Technical
- Relative Strength Index (RSI)
- CNNE 53.71
- ORKA 73.85
- Support Level
- CNNE $18.25
- ORKA $25.11
- Resistance Level
- CNNE $18.87
- ORKA $27.75
- Average True Range (ATR)
- CNNE 0.37
- ORKA 2.09
- MACD
- CNNE 0.05
- ORKA -0.00
- Stochastic Oscillator
- CNNE 83.33
- ORKA 86.26
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.